U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07910708) titled 'GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia' on Oct. 22.
Brief Summary: This study will evaluate GN001 in adults aged 18 to 75 years with CD19-positive relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia. GN001 is an investigational lentiviral vector-based treatment designed to generate CD19-targeted chimeric antigen receptor (CAR) T cells within the body.
The main purpose is to assess safety and tolerability at different doses. The study will also assess antitumor activity, the expansion and persistence of CAR T cells, and biological resp...